Experimental antibacterial activity of selective cyclooxygenase antagonist

Hayder M. Al-kuraishy, Ali I. Algareeb, Salah A. Al-windy

Abstract


Background: From the history of the development of pharmaceutical compounds it is evident that any drug may have the possibility of possessing diverse functions and thus may have useful activity in completely different fields of medicine and different studies showed that newer antimicrobials have revealed antimicrobial action involved in the management of diseases of non-infectious etiology. This study was done to determine in vitro antibacterial activity of selected selective cyclooxygenase-2 inhibitor.

Methods: Twenty two strains of gram positive and gram negative bacteria, which were isolated from skin and urinary tract infected patient. These bacteria were being cultured on specific optimal growth media. The antibacterial activity of selective COX-2 (meloxicam, celecoxib, valdecoxib and nimesulide). Inhibitors determined by measuring zone of inhibition and minimal inhibitory concentration (MIC).

Results: Results showed that MIC of celecoxib and meloxicam in µg/ml was ranged from 5-80µg/ml on selected bacteria compared with negative control distilled water (D.W) ,valdecoxib was 80-160µg/ml, while and nimesulide was ranged from 5-40 µg/ml .All the selected bacteria were showed sensitivity for all coxib used in this experimental study except Pseudomonas aeruginosa which showed resistant to meloxicam and valdecoxib, Klebsiella pneumoniae resist to nimesulide while Staphylococcus aureus was resist to valdecoxib. The smaller zone of inhibition showed by valdecoxib and celecoxib which was 3mm against Klebsiella pneumoniae, while the larger zone of inhibition showed by nimesulide which was 26mm against Escherichia coli.

Conclusions: In conclusion selective cyclooxygenase (cox-2) inhibitor possesses antibacterial activity this is especially for nimesulide and little by valdecoxib. Escherichia coli are sensitive bacteria to all coxib. Consequently; coxib may be regarded as anti-inflammatory and antibacterial agent especially for urinary tract infection where Escherichia coli are the major causative organism.


Keywords


Antibacterial, Cyclooxygenase-2 inhibitor, Zone of inhibition

Full Text:

PDF

References


Dastidar SG, Saha PK, Sanyamat B and Chakrabarty A. Antibacterial activities of ambodryl and bendadryl. J Appl Bact 1976;41:209-14.

Chattopadhyay D, Dastidar S and Chakrabarty A. Anti-microbial property of methdilazine and its synergism with antibiotics and some chemotherapeutic agents. Arzneim Forsch1988;38:869-72.

Roy K and Chakrabarty A. Anti-bacterial activities of anti-histamine triprolidine hydrochloride (actidil) and cross-resistances to antibiotics developed by experimentally derived mutants resistant to this drug. Indian J Med Microbiol 1994;12:9-18.

Dastidar S, Jairaj J, Mookerjee M and Chakrabarty A. Studieson anti-microbial effect of the anti-histaminic phenothiazine trimeprazine tartrate. Acta Microbiol Immun Hung 1997;44:241-7.

Molna J, Mandi Y and Kiraly J. Anti-bacterial

effect of some phenothiazine compounds and the R-factor elimination by chlorpromazine. Acta Microbiol Acad Sci Hung 1996;23:45-54.

Kristiansen J. Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall. Acta Path Microbiol Scand Sect B 1979;87:317-9.

Kristiansen J and Mortensen I. Anti-bacterial effect of four phenothiazines. Pharmacol Toxicol 1987;60:100-3.

Dastidar S, Chaudhuri A, Annadurai S, Ray S, Mookerjee M and Chakrabarty A. In vitro and in vivo anti-microbial action of fluphenazine. J Chemother 1995;7:201-6.

Mondal U, Niyogi S, Chakrabarty A. Anti-bacterial property of methyl-DOPA and development of antibiotic cross-resistances in m-DOPA mutants. Indian J Med Res1986;84:142-7.

Manna K and Dastidar S. The anti-hypertensive drug propranolol hydrochloride (carditap): its anti-bacterial property.. Proceedings of National Congress of IAMM (Image India, Calcutta), 2001;984:137-41.

Garcia-Rodriguez J. Invitro activity of non steroidal anti-inflammatory agents. Eur J Clin Microbial Infec Dis1999;15:418-20.

Komhoff M, Wang J, Cheng H, et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 2000; 57:414-22.

Van J, Bakhle Y andBotting R. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38:97-9.

Kurumbail R, Stewens A, Gierse J, McDonald J, Stegeman RA, Pak J, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384:644-8.

Pairet M and van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxigenase-1 andcyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res 1998;47:93-101.

Annadurai S, Basu S, Ray S, Dastidar S and, Chakrabarty A. Anti-bacterial activity of the anti-inflammatory agent diclofenac sodium. Indian J Exp Biol 1998;36:86-90.

Munoz-Criado S, Munoz-Bellido J and Garcia-Rodriguez J. Invitro activity of non steroidal anti-inflammatory agents, phenothiazines and anti-depressants against Brucellaspecies. Eur J Clin Microbial Infec Dis 1996;15:418-20.

Kurumbail RG, Stewens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature2002;384:644–81

Annadurai S, Basu S, Ray S, Dastidar S and Chakrabarty A. Anti-bacterial activity of the anti-inflammatory agent diclofenac sodium. Indian J Exp Biol 1998;36:86-90.

Barrow G and Feltham R. Cowan and Steel for identification of medical bacteria. (Cambridge University press, Cambridge, UK, 1993.

National Committee for Clinical Labrotory Standarded. Methode for dilution in antimicrobial Susceptibility Test. Approved Staandared. M2-A5 NCCLS,Villanova,PA1999.

Abu-El-Wahab ZH and El-sarrag MR. Derivative of phosphate shift base trasition and biological activity Spec Acta 2004;60:271-7.

Rainsford K. Profile and mechanism of gastrointestinal and other side effects of NSAID. AM J Med1999; 107:27-35.

CoruzziG, Menzzi A and Dobrilla G. Novel NSAID: What we have learned from animal studies. Curr Drug Target inflamm Allergy 2009;3:43-61.

Donneelly M. Review article: COX-2 inhibitor a new generation of safer NSAID? Aliment Phamacol Ther 2007;11:227-30.

Crofford LJ. Basic biology and clinical application of specific COX-2 inhibitor. Artharitis Rheum 2000;43:4-13.

Payan D and Katzung B. Non-steroidal anti-inflammatory drugs; nonopoid analgesics; drugs used in gout, In: Katzung BG (ed), Basic and clinical pharmacology, 6th ed. Appleton and Lange, USA 1995.

Alem M and Douglas L. Effects of aspirin and other nonsteroidal anti- inflammatory drugs on biofilms and planktonic cells of Candida albicans. Antimicrob Agents Chemother 2004;48:41-7.

Hecker M, Foegh M and Ramwell P. The eicosanoids: prostaglandins, thromboxanes, leukotrienes and related compounds. In: Katzung BG (ed) Basic and clinical pharmacology, 6th ed. Appleton and Lange, USA pp. 1995; 290-304.

Helle M, Brakenhoff J, de Groot E and Aarden L. Interleukin-6 is involved in interleukin-1 induced activities. Eur J Immunol 2006;18:957-9.

Annaduri S, Basu S, Ray S, Dastidar S and Chakrabarty A. Antimicrobial activity of the anti-inflammatory agent, diclofenac sodium. Indian J Exp Biol 2008;36:86-90.

Stevens D. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome? Clin Infect Dis 2009;21:977-80.

Madigan M, Martinko J and ParterJ. Microbial growth control. In: Brock TD (ed), Brock biology of microorganisms. 9th ed. Prentice HillInc, USA2000.

Mycek M, Harvey R and Champe P. Anti-inflammatory drugs, In: Lippincott’s illustrated reviews. 2nd ed Lippincott Williams and Wilkins, USA, pp. 2006; 401-20.

Michelle A, Carey J, Alyce B, John M, Robert L, et al. Contrasting effects of cyclooxygenase (cox-1) and cox2 deficiency on the host response to influenza A viral infection. J Immunol 2010;100:762-5.

Anurup M, Chanrima S, Aditya K, Jena R, et al. An investigation in vitro and vivo antimicrobial properties of the antidepressant amitriptyline hydrochloride. Brazillian Journal of microbiology 2010;41:635-42.

Schonthal A. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 2006;20(4):33-5.

Santic M, R Asare, I Skrobonja, S. Jones Y. Acquisition of the vacuolar ATPase proton pump and phagosome acidification are essential for escape of Francisellatularens is into the macrophage cytosol. Infect Immun 2008;76:2671-7.

Schonthal A. Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 2009;97:1465-8.